Cargando…

Antiretroviral drugs efavirenz, dolutegravir and bictegravir dysregulate blood-brain barrier integrity and function

The implementation of combined antiretroviral therapy (cART) significantly reduces the mortality associated with human immunodeficiency virus (HIV) infection. However, complications such as HIV-associated neurocognitive disorders (HAND) remain a major health concern. We hypothesized that the toxicit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Chang, Hoque, Tozammel, Bendayan, Reina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030948/ https://www.ncbi.nlm.nih.gov/pubmed/36969875 http://dx.doi.org/10.3389/fphar.2023.1118580

Ejemplares similares

SARS-CoV-2 infection dysregulates the expression of clinically relevant drug metabolizing enzymes in Vero E6 cells and membrane transporters in human lung tissues
por: Nwabufo, Chukwunonso K., et al.
Publicado: (2023)

Interaction between dolutegravir and folate transporters and receptor in human and rodent placenta
por: Gilmore, Julian C., et al.
Publicado: (2021)

Antiretroviral Treatment with Efavirenz Disrupts the Blood-Brain Barrier Integrity and Increases Stroke Severity
por: Bertrand, Luc, et al.
Publicado: (2016)

Peroxisome proliferator-activated receptor-gamma: potential molecular therapeutic target for HIV-1-associated brain inflammation
por: Omeragic, Amila, et al.
Publicado: (2017)

Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
por: Sax, Paul E., et al.
Publicado: (2018)

Reduction in the weight, gained due to dolutegravir, following switch to bictegravir
por: Saple, Dattatray, et al.
Publicado: (2022)

Concentration-Response Relationships of Dolutegravir and Efavirenz with Weight Change After Starting Antiretroviral Therapy
por: Griesel, Rulan, et al.
Publicado: (2022)

Potential pharmacological approaches for the treatment of HIV-1 associated neurocognitive disorders
por: Omeragic, Amila, et al.
Publicado: (2020)

Novel localization of folate transport systems in the murine central nervous system
por: Sangha, Vishal, et al.
Publicado: (2022)

Role of anti-inflammatory compounds in human immunodeficiency virus-1 glycoprotein120-mediated brain inflammation
por: Ashraf, Tamima, et al.
Publicado: (2014)

Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda
por: Twimukye, Adelline, et al.
Publicado: (2021)

Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study
por: Zash, Rebecca, et al.
Publicado: (2018)

Suppression of HIV in the first 12 months of antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens
por: da Silva, Gabriella Jomara, et al.
Publicado: (2023)

1033. One year of Bictegravir in Mexico City: Differences in the Neuropsychiatric Adverse Events vs. Efavirenz
por: Rodriguez, Victor
Publicado: (2020)

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir
por: Oliveira, Maureen, et al.
Publicado: (2018)

Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis
por: Nightingale, Sam, et al.
Publicado: (2016)

A Randomized Trial of Bictegravir or Dolutegravir with Emtricitabine and Tenofovir Alafenamide (F/TAF) Followed by Open Label Switch to Bictegravir/F/TAF Fixed Dose Combination
por: Sax, Paul E, et al.
Publicado: (2017)

Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV
por: Martínez-Sanz, Javier, et al.
Publicado: (2022)

Drug Transport and Metabolism in the Blood–Brain Barrier
por: Kapitulnik, Jaime
Publicado: (2011)

Will drug resistance against dolutegravir in initial therapy ever occur?
por: Wainberg, Mark A., et al.
Publicado: (2015)

Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
por: Deng, Lisi, et al.
Publicado: (2022)

1023. Suppressed Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide vs. Dolutegravir/Lamivudine: Virologic Failure and Durability
por: Pierone, Gerald, et al.
Publicado: (2023)

1561. Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Versus Dolutegravir (DTG)-Based 3-Drug Regimens in Adults With HIV Who Have Suboptimal Antiretroviral Adherence
por: Andreatta, Kristen, et al.
Publicado: (2023)

Regulation of ABC Drug Efflux Transporters in Human T-Cells Exposed to an HIV Pseudotype
por: Whyte-Allman, Sana-Kay, et al.
Publicado: (2021)

Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection
por: Chan, Phillip, et al.
Publicado: (2022)

Treatment Outcomes of Dolutegravir- Versus Efavirenz-Based Highly Active Antiretroviral Therapy Regimens Among Treatment-Naive People Living With HIV
por: Mahale, Prarthana R, et al.
Publicado: (2023)

Clinical Outcomes After Viremia Among People Receiving Dolutegravir vs Efavirenz-Based First-line Antiretroviral Therapy in South Africa
por: Asare, Kwabena, et al.
Publicado: (2023)

The Effects of Psychostimulant Drugs on Blood Brain Barrier Function and Neuroinflammation
por: Kousik, Sharanya M., et al.
Publicado: (2012)

Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China: a real-world assessment
por: Peng, Yongquan, et al.
Publicado: (2023)

Diagnostic accuracy of a point‐of‐care urine tenofovir assay, and associations with HIV viraemia and drug resistance among people receiving dolutegravir and efavirenz‐based antiretroviral therapy
por: Dorward, Jienchi, et al.
Publicado: (2023)

Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines
por: Phillips, Andrew N, et al.
Publicado: (2020)

A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy
por: Ochanda, Perez Nicholas, et al.
Publicado: (2022)

Cost-effectiveness of dolutegravir vs. efavirenz-based combined antiretroviral therapies in HIV-infected treatment-naive patients in a Nigerian treatment centre
por: Isah, Abdulmuminu, et al.
Publicado: (2023)

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
por: Song, Ivy, et al.
Publicado: (2014)

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
por: Griesel, Rulan, et al.
Publicado: (2020)

Bictegravir-Based Antiretroviral Therapy-Associated Accelerated Hyperglycemia and Diabetes Mellitus
por: Nolan, Nathanial S, et al.
Publicado: (2021)

Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection
por: Boffito, Marta, et al.
Publicado: (2020)

Efficacy and Tolerability of Lopinavir/Ritonavir- and Efavirenz-Based Initial Antiretroviral Therapy in HIV-1-Infected Patients in a Tertiary Care Hospital in Beijing, China
por: Su, Bin, et al.
Publicado: (2019)

Acute effects of focused ultrasound-induced increases in blood-brain barrier permeability on rat microvascular transcriptome
por: McMahon, Dallan, et al.
Publicado: (2017)

Comparative Safety and Changes in Immunologic and Virologic Parameters of Dolutegravir versus Efavirenz-Based Antiretroviral Therapies Among HIV Patients: A Retrospective Cohort Study
por: Ayal, Melese Alemnew, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ldesldansp40rqgp16nucq28u7